Thus, although targeting DDX3 should be carefully weighed in the context of its many physiological roles [42–45], our results raised the attractive possibility that treatment with DDX3 inhibitors could be a viable and broadly-effective approach to curtail viral replication and alleviate arenavirus infections in humans, either alone or in combination with ribavirin. Here, DDX3X is linked to Arenaviridae infectious disease.